In a multi-center study by Forbes et al., adverse events in patients with either STAT1 or STAT3 GOF treated with JAK inhibitors ruxolitinib (n = 16) or tofacitinib (n = 1) were transient thrombocytopenia, elevated transaminases and bilirubin, and viral infections such as herpes zoster (n = 2), viral bronchitis (n = 4), and gastroenteritis (n = 1). This evidence concerns the gene STAT1 and viral infectious disease.